Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trials

Medical device clinical trials from ClinicalTrials.gov

Trial ACTIVE_NOT_RECRUITING

PREVAIL Paclitaxel-coated Balloon in Small Coronary Disease and High-bleeding Risk Patients

NCT NCT06321757

Start 2024-02-26

View Details →

Trial COMPLETED

Transcutaneous Electrical Nerve Stimulation (TENS) for IUD Insertion Pain

NCT NCT06245655

Start 2024-03-25

View Details →

Trial ENROLLING_BY_INVITATION

A 90 Day Observational Study as an Extension to the Phase 3,Open Labeled Exploratory Study of RELiZORB

NCT NCT05635747

Start 2022-09-29

View Details →

Trial COMPLETED

Evaluation of a Therapeutic Mobile App for Depression

NCT NCT05601362

Start 2023-03-30

View Details →

Trial ACTIVE_NOT_RECRUITING

Lumbar Fusion With Porous Versus Non-Porous Cages

NCT NCT05583864

Start 2022-11-01

View Details →

Trial RECRUITING

Endurant Stent Graft System vs Excluder Endoprothesis: ADVANCE Trial

NCT NCT05378347

Start 2023-01-05

View Details →

Trial RECRUITING

Understanding Prefrontal and Medial Temporal Neuronal Responses to Algorithmic Cognitive Variables in Epilepsy Patients

NCT NCT05283811

Start 2021-06-01

View Details →

Trial TERMINATED

DIAMOND AF Post-Approval Study

NCT NCT05230524

Start 2022-02-28

View Details →

Trial ENROLLING_BY_INVITATION

Investigation of the Duration of Low-intensity Focused Ultrasound

NCT NCT05147103

Start 2022-08-26

View Details →

Trial ACTIVE_NOT_RECRUITING

Screening for High Frequency Malignant Disease

NCT NCT05117840

Start 2022-01-13

View Details →

Trial RECRUITING

Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) With or Without the Addition of DiviTum® Serum Thymidine Kinase 1 (TK1) Activity Testing

NCT NCT04968964

Start 2022-03-07

View Details →

Trial COMPLETED

The Efficacy and Safety of ALIC/NAcc-DBS for Treatment-refractory OCD

NCT NCT04967560

Start 2021-07-30

View Details →

Page 653 of 1067

↑